Key result
Reduced HRV and BPV predict mortality in critically ill COVID-19 patients requiring prolonged ICU stays.
Why the study?
Clinical correlates of dysautonomia and their impact on the disease course in critically ill COVID-19 patients were unknown.
Do reduced heart rate variability and blood pressure variability predict lethal outcome in critically ill COVID-19 patients?
Observational (n=361)
No
Do reduced heart rate variability and blood pressure variability predict lethal outcome in critically ill COVID-19 patients?
Effect estimate: Estimate -1.5 for HRV; Estimate -2.3 for BPV
p-value: p=0.028 for HRV; 0.008 for BPV
Reduced heart rate and blood pressure variability serve as clinical surrogates of dysautonomia and independently predict mortality in critically ill COVID-19 patients.
May inform prognostication in prolonged COVID-19 ICU stays; leaves open prospective validation and outcome impact.
BACKGROUND: Unpredictable vegetative deteriorations made the treatment of patients with acute COVID-19 on intensive care unit particularly challenging during the first waves of the pandemic. Clinical correlates of dysautonomia and their impact on the disease course in critically ill COVID-19 patients are unknown. METHODS: We retrospectively analyzed data collected during a single-center observational study (March 2020-November 2021) which was performed at the University Medical Center Hamburg-Eppendorf, a large tertiary medical center in Germany. All patients admitted to ICU due to acute COVID-19 disease during the study period were included (n = 361). Heart rate variability (HRV) and blood pressure variability (BPV) per day were used as clinical surrogates of dysautonomia and compared between survivors and non-survivors at different time points after admission. Intraindividual correlation of vital signs with laboratory parameters were calculated and corrected for age, sex and disease severity. RESULTS: Patients who deceased in ICU had a longer stay (median days ± IQR, survivors 11.0 ± 27.3, non-survivors 14.1 ± 18.7, P = 0.85), in contrast time spent under invasive ventilation was not significantly different (median hours ± IQR, survivors 322 ± 782, non-survivors 286 ± 434, P = 0.29). Reduced HRV and BPV predicted lethal outcome in patients staying on ICU longer than 10 days after adjustment for age, sex, and disease severity. Accordingly, HRV was significantly less correlated with inflammatory markers (e.g. CRP and Procalcitonin) and blood carbon dioxide in non-survivors in comparison to survivors indicating uncoupling between autonomic function and inflammation in non-survivors. CONCLUSIONS: Our study suggests autonomic dysfunction as a contributor to mortality in critically ill COVID-19 patients during the first waves of the pandemic. Serving as a surrogate for disease progression, these findings could contribute to the clinical management of COVID-19 patients admitted to the ICU. Furthermore, the suggested measure of dysautonomia and correlation with other laboratory parameters is non-invasive, simple, and cost-effective and should be evaluated as an additional outcome parameter in septic patients treated in the ICU in the future.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2023) conducted an observational in Acute COVID-19 (n=361). Reduced heart rate variability (HRV) and blood pressure variability (BPV) vs. Higher HRV and BPV was evaluated on Lethal outcome (mortality) in patients staying on ICU longer than 10 days (Estimate -1.5 for HRV; Estimate -2.3 for BPV, p=0.028 for HRV; 0.008 for BPV). Reduced heart rate variability and blood pressure variability significantly predicted lethal outcome in critically ill COVID-19 patients staying in the ICU longer than 10 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: